Although the tumor size trajectories in the combination group (CP + mAb-PA) for four other models (PH006, PH271, PH231, and PH471) were not significantly different from the CP + IgG2a group, all tended to have smaller tumors after combination therapy, except for PH231, in which trajectories are nearly overlaid. The gene discussed is CP; the disease is neoplasm.